{"id":3979,"date":"2021-06-09T12:15:22","date_gmt":"2021-06-09T11:15:22","guid":{"rendered":"https:\/\/ibb.uab.cat\/?p=3979"},"modified":"2021-06-09T12:36:53","modified_gmt":"2021-06-09T11:36:53","slug":"a-long-lasting-anti-covid-19-subcutaneous-vaccine-through-a-novel-industrially-competitive-and-biologically-safe-nanomimetic-concept-invita","status":"publish","type":"post","link":"https:\/\/ibb.uab.cat\/index.php\/2021\/06\/09\/a-long-lasting-anti-covid-19-subcutaneous-vaccine-through-a-novel-industrially-competitive-and-biologically-safe-nanomimetic-concept-invita\/","title":{"rendered":"\u201cA long-lasting anti-Covid-19 subcutaneous vaccine through a novel, industrially competitive and biologically safe nanomimetic concept (INVITA)\u201d"},"content":{"rendered":"\n
\"\"<\/figure><\/div>\n\n\n\n

De les 185 propostes que es van registrar a la convocat\u00f2ria, se n\u2019han finan\u00e7at un total de 32 projectes, amb un finan\u00e7ament total d\u2019uns 7M\u20ac, que s\u2019hauran de desenvolupar en un per\u00edode m\u00e0xim de 18 mesos. Un dels 7 projectes concedits a la UAB<\/strong>, estar\u00e0 liderat pel Prof. Antoni Villaverde, investigador de l\u2019IBB<\/strong>, i ser\u00e0 finan\u00e7at amb gaireb\u00e9 350.000 \u20ac<\/strong>. El projecte es titula \u201cA long-lasting anti-Covid-19 subcutaneous vaccine through a novel, industrially competitive and biologically safe nanomimetic concept (INVITA)\u201d i a part d\u2019involucrar diferents membres del grup de Biotecnologia de l\u2019IBB, compta tamb\u00e9 amb la participaci\u00f3 de 2 grups m\u00e9s de la UAB (Dra. Nerea Roher i Dr. Miguel Chill\u00f3n) aix\u00ed com tamb\u00e9 l\u2019IRTA-CReSA (Dra. Julia Vergara), la UPC (Dr. Rafael Cubarsi) i l\u2019Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau (Prof. Ramon Mangues). A m\u00e9s a m\u00e9s, t\u00e9 el suport de l\u2019Oficina de Valoritzaci\u00f3 i Patents de la UAB per maximitzar les oportunitats d\u2019explotaci\u00f3 dels resultats que se\u2019n derivin.  <\/p>\n\n\n\n

A mitjans de maig, van tenir lloc les jornades\u00a0kick-off\u00a0<\/em>de presentaci\u00f3 del projecte a tots els membres de l\u2019equip per\u00a0engegar-ne l\u2019execuci\u00f3\u00a0del projecte\u00a0que\u00a0pret\u00e9n desenvolupar\u00a0la\u00a0tecnologia\u00a0INVITA. Aquesta tecnologia es construir\u00e0\u00a0a partir d\u2019una plataforma gen\u00e8rica pr\u00e8viament patentada\u00a0pel grup i ser\u00e0\u00a0senzilla,\u00a0segura,\u00a0robusta i potent. INVITA est\u00e0\u00a0basada en l\u2019alliberaci\u00f3 lenta de nanopart\u00edcules\u00a0via\u00a0dip\u00f2sits vacunals administrats de forma\u00a0subcut\u00e0nia,\u00a0que podria resoldre\u00a0alguns dels\u00a0problemes de vacunaci\u00f3 per Covid-19 i transversalment per a altres malalties infeccioses.\u00a0L\u2019estimulaci\u00f3 cont\u00ednua del sistema immunitari\u00a0gr\u00e0cies a aquestes nanopart\u00edcules alliberades\u00a0generar\u00e0 una resposta protectora forta i duradora en abs\u00e8ncia de riscos biol\u00f2gics per al pacient i el medi ambient.\u00a0A m\u00e9s a m\u00e9s, INVITA\u00a0oferir\u00e0 una vacuna totalment competitiva pel que fa als costos de producci\u00f3, efectivitat i problemes\u00a0regulatoris. Per tant, ens trobem en un projecte que podria culminar en una nova aposta de vacunaci\u00f3\u00a0altament competitiva en el mercat actual.\u00a0\u00a0<\/p>\n\n\n\n

L\u2019any passat la Secretaria d\u2019Universitats i Recerca, i gr\u00e0cies a la tramitaci\u00f3 d\u2019AGAUR, va llen\u00e7ar una l\u00ednia d\u2019ajuts anomenada \u201cReplegar-se per cr\u00e9ixer: l’impacte de les pand\u00e8mies en un m\u00f3n sense fronteres visibles\u201d (PAND\u00c8MIES 2020) per finan\u00e7ar projectes\u00a0consorciats\u00a0que pretenguessin analitzar l\u2019impacte del Covid-19 o futures pand\u00e8mies en la societat i poder-hi fer front mitjan\u00e7ant nous models predictius, preventius o d\u2019actuaci\u00f3.\u00a0\u00a0<\/p>\n\n\n\n

(Image modified from\u00a0https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/advs.201902420<\/a>) Editado<\/p>\n","protected":false},"excerpt":{"rendered":"

De les 185 propostes que es van registrar a la convocat\u00f2ria, se n\u2019han finan\u00e7at un total de 32 projectes, amb un finan\u00e7ament total d\u2019uns 7M\u20ac, que s\u2019hauran de desenvolupar en un per\u00edode m\u00e0xim de 18 mesos. Un dels 7 projectes concedits a la UAB, estar\u00e0 liderat pel Prof. Antoni Villaverde, investigador de l\u2019IBB, i ser\u00e0 finan\u00e7at amb gaireb\u00e9 350.000 \u20ac. El projecte es […]<\/p>\n","protected":false},"author":65,"featured_media":3980,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts\/3979"}],"collection":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/users\/65"}],"replies":[{"embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/comments?post=3979"}],"version-history":[{"count":4,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts\/3979\/revisions"}],"predecessor-version":[{"id":3993,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/posts\/3979\/revisions\/3993"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/media\/3980"}],"wp:attachment":[{"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/media?parent=3979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/categories?post=3979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibb.uab.cat\/index.php\/wp-json\/wp\/v2\/tags?post=3979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}